Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible

robotics and the developer of robotic technology for accurate 3D

control of catheter movement, today announced it has named veteran

medical device sales and marketing executive Joe Guido Vice President

Marketing and Business Development. Mr. Guido will report directly to

President and Chief Executive Officer Bruce J Barclay.

Joe has more than 20 years of sales and marketing experience for a

variety of medical device companies including Intuitive Surgical,

Abbott Vascular Devices and Stryker Endoscopy, generating experience

in cardiology, vascular and surgical markets. Throughout his career,

Mr. Guido has excelled as a sales and marketing professional,

capturing record sales growth through innovative strategies across the

medical device industry.

"Joe is a proven leader with an outstanding career commercializing

products in a breadth of markets, making him an excellent addition to

the team," Barclay said. "Joe's track record of developing and

executing successful global marketing strategies, launching new

products, capturing market share in both established and emerging

markets, and forging long-term partnerships with both hospitals and

physicians, will prove invaluable to Hansen Medical. This will be

particularly evident as we build on our EP business and pursue

opportunities in the vascular market with the launch of our Magellan

Robotic System in Europe and with the expected launch of that product

in the U.S."

"I am excited to be joining the Hansen Medical team at this important

inflection point in the Company's history," said Guido. "Flexible

robotics in both vascular and EP applications has the potential to

transform how interventional procedures are performed. I believe

Hansen is uniquely positioned to take advantage of this opportunity

with its compelling value proposition to hospitals, physicians and

patients. In addition, the Company has developed a strong foundation

for a focused and controlled launch strategy with an enhanced sales

team, robust training and physician support in preparation for the

expected launch of the Magellan System in the U.S. Further, I am

excited to work with the team at this critical time in order to drive

a successful go-to-market strategy and realize our position as an

industry leader in flexible robotics."

Prior to joining Hansen Medical, Joe spent five years as Vice

President of Sales and Marketing at Novare Surgical Systems, Inc., a

privately-held medical device company that developed innovative

products for minimally invasive surgery. Previous to Novare, he was

the Director of Global Strategic Marketing for Abbott Vascular

Devices' vessel closure business, and Vice President of Global

Marketing at Intuitive Surgical, a public medical device company

specializing in surgical robotic systems. While at Intuitive, Mr.

Guido led the marketing group while the organization experienced

revenue growth of nearly 40% year-over-year. Joe also served 5 years

at Stryker Endoscopy, a division of publically-traded Stryker

Corporation, where he last operated as Director of Marketing, driving

product strategy and business development efforts that generated over

$150 million for the division.

About Hansen Medical, Inc. Hansen Medical, Inc., based in Mountain

View, California, develops products and technology using robotics for

the accurate positioning, manipulation and control of catheters and

catheter-based technologies. The Company's Sensei@ X Robotic Catheter

System and Artisan Control Catheter were cleared by the U.S. Food and

Drug Administration for manipulation and control of certain mapping

catheters in electrophysiology (EP) procedures. This robotic catheter

system is compatible with fluoroscopy, ultrasound, 3D surface map and

patient electrocardiogram data. In the United States, the Sensei

System is not approved for use in guiding ablation procedures; this

use remains experimental. The U.S. product labeling therefore provides

that the safety and effectiveness of the Sensei X System and Artisan

Control Catheter for use with cardiac ablation catheters in the

treatment of cardiac arrhythmias, including atrial fibrillation (AF),

have not been established. In the European Union, the Sensei X System

and Artisan Control Catheter are cleared for use during EP procedures,

such as guiding catheters in the treatment of AF, and the Lynx@

Robotic Ablation Catheter is cleared for the treatment of AF. The

Company's Magellan Robotic System, NorthStar Robotic Catheter and

related accessories, which are intended to facilitate navigation to

anatomical targets in the peripheral vasculature and subsequently

provide a conduit for manual placement of therapeutic devices, have

undergone conformity assessment and CE marking and are commercially

available in the European Union. In the U.S., the Magellan Robotic

System, the NorthStar Robotic Catheter and accessories are the

subject of a current filing with the FDA and are not commercially

available. Additional information can be found at

Forward-Looking StatementsThis press release contains forward-looking

statements regarding, among other things, statements relating to

goals, plans, expectations, objectives, milestones and future events.

All statements, other than statements of historical fact, are

statements that could be deemed forward-looking statements, including

statements containing the words "plan," "expects," "potential,"

"believes," "goal," "estimate," "anticipates," and similar words.

These statements are based on the current estimates and assumptions of

our management as of the date of this press release and are subject to

risks, uncertainties, changes in circumstances and other factors that

may cause actual results to differ materially from the information

expressed or implied by forward-looking statements made in this press

release. Examples of such statements include statements about the

anticipated growth of Hansen's flexible robotic technology in both EP

and vascular applications. Important factors that could cause actual

results to differ materially from those indicated by such

forward-looking statements include, among others: engineering,

regulatory and sales challenges in developing new products and

entering new markets; potential safety and regulatory issues that

could slow or suspend our sales; the uncertain timelines, costs and

results of pre-clinical and clinical trials; the rate of adoption of

our systems and the rate of use of our catheters; the scope and

validity of intellectual property rights applicable to our products;

competition from other companies; our ability to recruit and retain

key personnel; our ability to maintain our remedial actions over

previously reported material weaknesses in internal controls over

financial reporting; the effect of credit, financial and economic

conditions on capital spending by our potential customers; our ability

to manage expenses and obtain additional financing; and other risks

more fully described in the "Risk Factors" section of our Annual

Report on Form 10-K for the year ended December 31, 2011 filed with

the SEC on March 15, 2012 and the risks discussed in our other reports

filed with the SEC. Given these uncertainties, you should not place

undue reliance on the forward-looking statements in this press

release. We undertake no obligation to revise or update information

herein to reflect events or circumstances in the future, even if new

information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart

Design), and Sensei are registered trademarks of Hansen Medical, Inc.

in the United States and other countries.